Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 25
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Daglas, R. Cotton, S.M. Allott, K. Yücel, M. Macneil, C.A. Hasty, M.K. Murphy, B. Pantelis, C. Hallam, K.T. Henry, L.P. Conus, P. Ratheesh, A. Kader, L. Wong, M.TH. McGorry, P.D. and Berk, M. 2016. A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study. European Psychiatry, Vol. 31, p. 20.

    Chakrabarty, Trisha Kozicky, Jan-Marie Torres, Ivan J. Lam, Raymond W. and Yatham, Lakshmi N. 2015. Verbal memory impairment in new onset bipolar disorder: Relationship with frontal and medial temporal morphology. The World Journal of Biological Psychiatry, Vol. 16, Issue. 4, p. 249.

    Ehrlich, André Schubert, Florian Pehrs, Corinna and Gallinat, Jürgen 2015. Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder. Psychiatry Research: Neuroimaging, Vol. 233, Issue. 2, p. 73.

    de Sousa, Rafael T Machado-Vieira, Rodrigo Zarate, Carlos A and Manji, Husseini K 2014. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opinion on Therapeutic Targets, Vol. 18, Issue. 10, p. 1131.

    Adler, Caleb M. DelBello, Melissa P. Weber, Wade A. Jarvis, Kelly B. Welge, Jeffrey Chu, Wen-Jang Rummelhoff, Emily Kim, Mi-Jung Lee, Jing-Huei and Strakowski, Stephen M. 2013. Neurochemical Effects of Quetiapine in Patients With Bipolar Mania. Journal of Clinical Psychopharmacology, Vol. 33, Issue. 4, p. 528.

    Atmaca, Murad and Yildirim, Hanefi 2012. Altered Neurochemical Ingredient of Hippocampus in Patients with Bipolar Depression. Depression Research and Treatment, Vol. 2012, p. 1.

    Atmaca, Murad Yildirim, Hanefi Gurok, M. Gurkan Akyol, Muammer and Koseoglu, Filiz 2012. Hippocampal Neurochemical Pathology in Patients with Panic Disorder. Psychiatry Investigation, Vol. 9, Issue. 2, p. 161.

    Chang, Kiki DelBello, Melissa Chu, Wen-Jang Garrett, Amy Kelley, Ryan Mills, Neil Howe, Meghan Bryan, Holly Adler, Cal Eliassen, Jim Spielman, Daniel and Strakowski, Stephen M. 2012. Neurometabolite Effects of Response to Quetiapine and Placebo in Adolescents with Bipolar Depression. Journal of Child and Adolescent Psychopharmacology, Vol. 22, Issue. 4, p. 261.

    Chepenik, Lara G. Wang, Fei Spencer, Linda Spann, Marisa Kalmar, Jessica H. Womer, Fay Kale Edmiston, E. Pittman, Brian and Blumberg, Hilary P. 2012. Structure–function associations in hippocampus in bipolar disorder. Biological Psychology, Vol. 90, Issue. 1, p. 18.

    Kraguljac, Nina Vanessa Reid, Meredith White, David Jones, Rebecca den Hollander, Jan Lowman, Deborah and Lahti, Adrienne Carol 2012. Neurometabolites in schizophrenia and bipolar disorder — A systematic review and meta-analysis. Psychiatry Research: Neuroimaging, Vol. 203, Issue. 2-3, p. 111.

    Shahana, Nasrin DelBello, Melissa Chu, Wen-Jang Jarvis, Kelly Fleck, David Welge, Jeffrey Strakowski, Stephen and Adler, Caleb 2011. Neurochemical alteration in the caudate: Implications for the pathophysiology of bipolar disorder. Psychiatry Research: Neuroimaging, Vol. 193, Issue. 2, p. 107.

    Brambilla, Paolo and Soares, Jair C. 2010. Bipolar Disorder.

    Germaná, C. Kempton, M. J. Sarnicola, A. Christodoulou, T. Haldane, M. Hadjulis, M. Girardi, P. Tatarelli, R. and Frangou, S. 2010. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatrica Scandinavica, Vol. 122, Issue. 6, p. 481.

    Atmaca, Murad 2009. Valproate and neuroprotective effects for bipolar disorder. International Review of Psychiatry, Vol. 21, Issue. 4, p. 410.

    Berk, Michael Malhi, Gin S. Hallam, Karen Gama, Clarissa S. Dodd, Seetal Andreazza, Ana Cristina Frey, Benício N. and Kapczinski, Flavio 2009. Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. Journal of Affective Disorders, Vol. 114, Issue. 1-3, p. 1.

    Henin, Aude Micco, Jamie A. Wozniak, Janet Briesch, Jacquelyn M. Narayan, Angela J. and Hirshfeld-Becker, Dina R. 2009. Neurocognitive Functioning in Bipolar Disorder. Clinical Psychology: Science and Practice, Vol. 16, Issue. 2, p. 231.

    Langan, C and McDonald, C 2009. Neurobiological trait abnormalities in bipolar disorder. Molecular Psychiatry, Vol. 14, Issue. 9, p. 833.

    Ma, Dan Guest, Paul C and Bahn, Sabine 2009. Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis. Bioanalysis, Vol. 1, Issue. 9, p. 1615.

    Bian, Qian Kato, Takahiro Monji, Akira Hashioka, Sadayuki Mizoguchi, Yoshito Horikawa, Hideki and Kanba, Shigenobu 2008. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-γ. Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Issue. 1, p. 42.

    Brambilla, Paolo Hatch, John P. and Soares, Jair C. 2008. Limbic changes identified by imaging in bipolar patients. Current Psychiatry Reports, Vol. 10, Issue. 6, p. 505.


Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine

  • DOI:
  • Published online: 09 November 2006

Background. No study to date has examined the effects of mood stabilizer alone and the combination of mood stabilizer and atypical antipsychotic, quetiapine, on hippocampal neurochemical markers of bipolar disordered patients concurrently. We therefore undertook a proton magnetic resonance spectroscopy (1H MRS) study of drug-free patients with bipolar disorder (drug-free group), patients undergoing valproate treatment (valproate group), patients administered valproate+quetiapine (valprote+quetiapine group) and healthy controls, focusing on the in vivo neuroanatomy of the hippocampus.

Method. Thirty patients from the Firat University School of Medicine Department of Psychiatry and 10 healthy controls gave written informed consent to participate in the study. The patients and controls underwent proton magnetic resonance spectroscopic imaging (1H MRSI), and measures of N-acetylaspartate (NAA), choline-containing compounds (CHO), and creatine+phosphocreatine (CRE) in hippocampal regions were obtained.

Results. The drug-free patients had significantly lower NAA/CRE and NAA/CHO ratios compared with the valproate and valproate+quetiapine groups and the healthy controls. The lower NAA/CRE and NAA/CHO ratios remained statistically significant even after covarying for age or whole brain volume compared with the valproate and valproate+quetiapine groups and healthy controls. In post hoc comparisons, a significant difference was found between the valproate+quetiapine group and the valproate group only with regard to NAA/CHO.

Conclusion. Our findings suggest that valproate has a neuroprotective effect. In post hoc comparisons, a significant difference was found between the valproate+quetiapine and the valproate group with regard to NAA/CHO, indicating that the addition of quetiapine further increases the level of NAA and provides an additional neuroprotective effect.

Corresponding author
Firat (Euphrates) Universitesi, Firat Tip Merkezi, Psikiyatri Anabilim Dali, 23119 Elazig, Turkey. (Email:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *